Fagopyrum dibotyo nutraceuticals and methods of their use are provided. The disclosed F. dibotyo nutraceuticals are useful to improve or increase liver function and to treat liver diseases, especially those caused by viral hepatitis. In some embodiments, the F. dibotyo nutraceuticals also contain supplementary botanical extracts to confer additional health benefits.

Fagopyrum dibotyo nutraceuticals and methods of their use are provided. The disclosed F. dibotyo nutraceuticals are useful to improve or increase liver function and to treat liver diseases, especially those caused by viral hepatitis. In some embodiments, the F. dibotyo nutraceuticals also contain supplementary botanical extracts to confer additional health benefits.

The present disclosure relates to a pharmaceutical composition for preventing or treating respiratory diseases and a food composition for preventing or relieving respiratory diseases comprising a mixed extract of Dioscoreae rhizoma, Taraxaci herba and Schizonepetae spica as an active ingredient. A composition comprising a mixed extract of Dioscoreae rhizoma, Taraxaci herba and Schizonepetae spica of the present disclosure has an advantage of preventing respiratory diseases and relieving the symptoms of respiratory diseases, restores damages in the lung tissue and has efficacy for inhibiting inflammation, oxidative stress and ageing reactions induced by fine dust. More particularly, the composition of the present disclosure increases the expression of a telomerase which extends the length of a telomere, and thus is expected to fundamentally treat degenerative respiratory diseases induced by fine dust unlike existing symptom alleviating agent.

The present disclosure relates to a pharmaceutical composition for preventing or treating respiratory diseases and a food composition for preventing or relieving respiratory diseases comprising a mixed extract of Dioscoreae rhizoma, Taraxaci herba and Schizonepetae spica as an active ingredient. A composition comprising a mixed extract of Dioscoreae rhizoma, Taraxaci herba and Schizonepetae spica of the present disclosure has an advantage of preventing respiratory diseases and relieving the symptoms of respiratory diseases, restores damages in the lung tissue and has efficacy for inhibiting inflammation, oxidative stress and ageing reactions induced by fine dust. More particularly, the composition of the present disclosure increases the expression of a telomerase which extends the length of a telomere, and thus is expected to fundamentally treat degenerative respiratory diseases induced by fine dust unlike existing symptom alleviating agent.

The present disclosure relates to a pharmaceutical composition for preventing or treating respiratory diseases and a food composition for preventing or relieving respiratory diseases comprising a mixed extract of Dioscoreae rhizoma, Taraxaci herba and Schizonepetae spica as an active ingredient. A composition comprising a mixed extract of Dioscoreae rhizoma, Taraxaci herba and Schizonepetae spica of the present disclosure has an advantage of preventing respiratory diseases and relieving the symptoms of respiratory diseases, restores damages in the lung tissue and has efficacy for inhibiting inflammation, oxidative stress and ageing reactions induced by fine dust. More particularly, the composition of the present disclosure increases the expression of a telomerase which extends the length of a telomere, and thus is expected to fundamentally treat degenerative respiratory diseases induced by fine dust unlike existing symptom alleviating agent.

The present disclosure relates to a pharmaceutical composition for preventing or treating respiratory diseases and a food composition for preventing or relieving respiratory diseases comprising a mixed extract of Dioscoreae Rhizoma, Taraxaci Herba and Schizonepetae Spica as an active ingredient. A composition comprising a mixed extract of Dioscoreae Rhizoma, Taraxaci Herba and Schizonepetae Spica of the present disclosure has an advantage of preventing respiratory diseases and relieving the symptoms of respiratory diseases, restores damages in the lung tissue and has efficacy for inhibiting inflammation, oxidative stress and ageing reactions induced by fine dust. More particularly, the composition of the present disclosure increases the expression of a telomerase which extends the length of a telomere, and thus is expected to fundamentally treat degenerative respiratory diseases induced by fine dust unlike existing symptom alleviating agents.

The present disclosure relates to a pharmaceutical composition for preventing or treating respiratory diseases and a food composition for preventing or relieving respiratory diseases comprising a mixed extract of Dioscoreae Rhizoma, Taraxaci Herba and Schizonepetae Spica as an active ingredient. A composition comprising a mixed extract of Dioscoreae Rhizoma, Taraxaci Herba and Schizonepetae Spica of the present disclosure has an advantage of preventing respiratory diseases and relieving the symptoms of respiratory diseases, restores damages in the lung tissue and has efficacy for inhibiting inflammation, oxidative stress and ageing reactions induced by fine dust. More particularly, the composition of the present disclosure increases the expression of a telomerase which extends the length of a telomere, and thus is expected to fundamentally treat degenerative respiratory diseases induced by fine dust unlike existing symptom alleviating agents.

The present disclosure relates to a pharmaceutical composition for preventing or treating respiratory diseases and a food composition for preventing or relieving respiratory diseases comprising a mixed extract of Dioscoreae Rhizoma, Taraxaci Herba and Schizonepetae Spica as an active ingredient. A composition comprising a mixed extract of Dioscoreae Rhizoma, Taraxaci Herba and Schizonepetae Spica of the present disclosure has an advantage of preventing respiratory diseases and relieving the symptoms of respiratory diseases, restores damages in the lung tissue and has efficacy for inhibiting inflammation, oxidative stress and ageing reactions induced by fine dust. More particularly, the composition of the present disclosure increases the expression of a telomerase which extends the length of a telomere, and thus is expected to fundamentally treat degenerative respiratory diseases induced by fine dust unlike existing symptom alleviating agents.

This is an invention of a process and combination of ingredients in producing an novel herbal energy tea that is ready to drink. This tea is composed of elderberry dandelion, rose petals and rose hips, Mexican honeysuckle, yohimbe and agave nectar. This tea is yohimbe, elderberry, and Mexican honeysuckle based. The tea is not tea leaf based. There are currently no other products on the market in the United States that are similar to this product. It is the first, a novelty. The process of making an organic drinkable herbal energy tea product also includes the distinct process of using distilled water and or spring water. This also makes the process distinct and novel, because it is the first process that does not use municipal filtered water (which may contain cross contaminants) in the production of energy tea drinks. In addition yohimbe (tree bark) is the stimulant of choice as opposed to caffeine and other market stimulants. The sum of ingredients included in the process and production work synergistically to support vital organ function.

Brewing the ingredients require a short process of initial high heat of up to 212 degrees Fahrenheit, then simmering for 1 and a half hours at a temperature of 75 degrees. After simmering, the tea goes through a double micro filtration process extracting solid waste by-products. Thereafter, sweeteners and extracts are mixed and added to the warm cooling brew arriving the product to final settle and cool ready for storage or distribution.

This is an invention of a process and combination of ingredients in producing an novel herbal energy tea that is ready to drink. This tea is composed of elderberry dandelion, rose petals and rose hips, Mexican honeysuckle, yohimbe and agave nectar. This tea is yohimbe, elderberry, and Mexican honeysuckle based. The tea is not tea leaf based. There are currently no other products on the market in the United States that are similar to this product. It is the first, a novelty. The process of making an organic drinkable herbal energy tea product also includes the distinct process of using distilled water and or spring water. This also makes the process distinct and novel, because it is the first process that does not use municipal filtered water (which may contain cross contaminants) in the production of energy tea drinks. In addition yohimbe (tree bark) is the stimulant of choice as opposed to caffeine and other market stimulants. The sum of ingredients included in the process and production work synergistically to support vital organ function.

Brewing the ingredients require a short process of initial high heat of up to 212 degrees Fahrenheit, then simmering for 1 and a half hours at a temperature of 75 degrees. After simmering, the tea goes through a double micro filtration process extracting solid waste by-products. Thereafter, sweeteners and extracts are mixed and added to the warm cooling brew arriving the product to final settle and cool ready for storage or distribution.